Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Å©·Ðº´¿¡ ÇÕº´µÈ Á÷ÀåÁú·çÀÇ ÀÓ»ó°æ°ú Clinical Outcome of a Rectovaginal Fistula in Crohn¡¯s Disease

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2007³â 23±Ç 1È£ p.10 ~ 15
Á¤Ãá½Ä, À̵¿±Ù, George Bruce D., Mortensen Neil J.,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Ãá½Ä ( Chung Choon-Sik ) 
ÇѼֺ´¿ø ¿Ü°ú

À̵¿±Ù ( Lee Dong-Keun ) 
ÇѼֺ´¿ø ¿Ü°ú
 ( George Bruce D. ) 
Department of Colorectal Surgery, John Radcliffe Hospital, Oxford, U.K.
 ( Mortensen Neil J. ) 
Department of Colorectal Surgery, John Radcliffe Hospital, Oxford, U.K.

Abstract

¸ñÀû: Å©·Ðº´Àº Àü À§Àå°ü¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ¾î ±Ë¾ç¼º ´ëÀå¿°¿¡ ºñÇØ ´Ù¾çÇÑ Áõ»óÀÌ ¹ßÇöµÇ¸ç, ƯÈ÷ ½ÉÇÑ Ç×¹®ÁÖÀ§ ¿°Áõ¼º ÁúȯÀÇ ´ëºÎºÐÀº Å©·Ðº´ÀÌ´Ù. Å©·Ðº´¿¡ ÇÕº´µÈ Á÷ÀåÁú·çÀÇ ³»°úÀû ¾à¹°Ä¡·á ¹× ´Ù¾çÇÑ ¿Ü°úÀûÄ¡·á °æ°ú¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

¹æ¹ý: 1994³âºÎÅÍ 2003³â±îÁö John Radcliffe (Oxford, UK) º´¿ø¿¡ µî·ÏµÈ 422¸í(¿©ÀÚ; 212)ÀÇ Å©·Ðº´ ȯÀÚÁß Áø´Ü´ç½Ã ȤÀº º´ÀÇ °æ°úµµÁß Á÷ÀåÁú·ç°¡ ÇÕº´µÈ 21¸íÀÇ È¯ÀÚ¸¦ Á¶»çÇÏ¿´´Ù. ¸ðµç ȯÀÚ´Â ÀÓ»óÀû, ¹æ»ç¼±ÇÐÀû, ³»½Ã°æÀû ȤÀº / ±×¸®°í º´¸®Á¶Á÷°Ë»ç°á°ú Å©·Ðº´À¸·Î È®ÁøµÇ¾ú´Ù.

°á°ú: ȯÀÚÀÇ Æò±Õ ¿¬·ÉÀº 38¼¼(26¡­81)¿´°í, Æò±Õ ÃßÀû±â°£Àº 44°³¿ù(13¡­104)À̾ú´Ù. °°Àº ±â°£µ¿¾È Á÷ÀåÁú·ç·Î Ä¡·á ¹ÞÀº 70¿¹ Áß Å©·Ðº´¿¡ ÇÕº´µÈ ¿¹(30%)°¡ °¡Àå ¸¹¾Ò´Ù. Áø´Ü Àü Å©·Ðº´ÀÇ Æò±Õ ÀÌȯ±â°£Àº 6³â(0¡­30)À̾ú´Ù. 12¿¹´Â Ä¡·ç°¡ µ¿¹ÝµÇ¾ú°í, 3¿¹´Â 2°³ÀÇ Á÷ÀåÁú·ç°¡ ÀÖ¾ú´Ù. ´Ù¸¥ ¿¹¿¡ ºñÇØ ºñ±³Àû ±ä ´©°üÀ» °¡Áø 3¿¹´Â ¼¼ÅæÄ¡·á ÈÄ fibrin glue (commercial kit;Beriplast¨Þ, Aventis Behring, Sussex, United Kingdom)Ä¡·á¸¦ ÇÏ¿´À¸³ª ¸ðµÎ Àç¹ßÇÏ¿´´Ù. ¼¼Å漳ġ ¹× Anti-TNF-¥á (infliximab) Ä¡·á 6¿¹ Áß 5¿¹´Â Áõ»óÀÌ È£ÀüµÇ¾úÀ¸³ª ´©°üÀÌ Æó¼âµÇÁö´Â ¾Ê¾Ò´Ù. °æÇ×¹® ȤÀº °æÁúÀüÁøÇÇÆǼúÀ» ½ÃÇà¹ÞÀº 8¿¹ Áß 3¿¹´Â Àç¹ß¾øÀÌ ´©°üÀÌ Æó¼âµÇ¾úÀ¸³ª 2¿¹´Â Àç¹ßÇÏ¿´°í, 3¿¹´Â °è¼ÓµÇ´Â ¿°Áõ ¹× Ç×¹®Á÷Àå ÇùÂøÀ¸·Î Á÷ÀåÀýÁ¦¼ö¼úÀ» ¹Þ¾Ò´Ù. º´ÀÇ °æ°ú Áß ¿ìȸÀå·ç¼ö¼úÀ» ¹ÞÀº 16¿¹ Áß 4¿¹´Â ´©°üÀÌ Æó¼âµÇ¾ú´Ù. Á÷ÀåÇ×¹®ÇùÂø, Áö¼ÓÀûÀÎ ÃâÇ÷, Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê°í ¾ÇÈ­µÇ´Â Ç×¹®¿°ÁõÀ¸·Î 8¿¹´Â Á÷Àå ÀýÁ¦¼ö¼úÀ» ¹Þ¾Ò´Ù.

°á·Ð: Å©·Ðº´¿¡ ÇÕº´µÈ Á÷ÀåÁú·ç¿¡ ´ëÇÑ ´Ù¾çÇÑ ³».¿Ü°úÀû Ä¡·á´Â ¾î´À Á¤µµÀÇ Ä¡·á¼ºÀûÀ» º¸¿´À¸³ª ÁøÇàµÇ´Â Ç×¹®ÁÖÀ§ ¿°Áõ, Á÷ÀåÇ×¹® ÇùÂø ¹× ÃâÇ÷À» µ¿¹ÝÇÏ´Â Á÷ÀåÁú·ç´Â Á÷ÀåÀýÁ¦¼ö¼úÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose: The aim of this study is to analyze the outcome of a variety of treatments, including local surgical treatments, diverting stoma, and combined medical therapy, for patients with a rectovaginal fistula complicating Crohn¡¯s disease.

Methods: Between 1994 and 2003, twenty-one patients with a rectovaginal fistula complicating Crohn¡¯s disease from a prospectively compiled 422-patient Crohn¡¯s disease database were reviewed.

Results: All three patients treated by seton and fibrin glue recurred despite having relatively long tracts. Of six patients with infliximab treatment combined with a seton procedure, five patients had an improvement of their symptoms, but were not cured. Of eight patients with a transanal or endovaginal advancement flap techniques, three had successful closure, three eventually required a proctectomy, and two had a recurrent fistula without symptoms. Four (2 without any local treatments, and 2 with seton placement) of 16 patients who had a diverting stoma during treatment had successful closure. All proctectomy patients (n=8) had rectal involvement of Crohn¡¯s disease. Two patients who underwent a proctectomy with a presumptive diagnosis of ulcerative colitis and indeterminate colitis turned out to have Crohn¡¯s disease. Overall, except for the proctectomy patients, seven patients (54%) had successful closure, but six (four without symptoms, and two with symptoms) following a wide spectrum of treatments had recurrence after a mean follow-up of 44 months.

Conclusion: Combining different treatments for a rectovaginal fistula in Crohn¡¯s disease can be successful in a reasonable number of cases. The presence of uncontrolled perianal sepsis and/or complicated anorectal problems is likely to lead to a proctectomy. J Korean Soc Coloproctol 2007;23:10-15

Å°¿öµå

Å©·Ðº´;Á÷ÀåÁú·ç;°æÇ×¹® ÀüÁøÇÇÆǼú;°æÁú ÀüÁøÇÇÆǼú;Á÷ÀåÀýÁ¦¼ú
Crohn¡¯s disease;Rectovaginal fistula;Transanal advancement flap;Endovaginal advancement flap;Proctectomy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS